6z4s
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='6z4s' size='340' side='right'caption='[[6z4s]], [[Resolution|resolution]] 2.71Å' scene=''> | <StructureSection load='6z4s' size='340' side='right'caption='[[6z4s]], [[Resolution|resolution]] 2.71Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'> | + | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6Z4S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6Z4S FirstGlance]. <br> |
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.707Å</td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.707Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=Q6Q:2-[[1-(7-chloranylquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl]carbonylamino]adamantane-2-carboxylic+acid'>Q6Q</scene></td></tr> | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=Q6Q:2-[[1-(7-chloranylquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl]carbonylamino]adamantane-2-carboxylic+acid'>Q6Q</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z4s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z4s OCA], [https://pdbe.org/6z4s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z4s RCSB], [https://www.ebi.ac.uk/pdbsum/6z4s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z4s ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z4s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z4s OCA], [https://pdbe.org/6z4s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z4s RCSB], [https://www.ebi.ac.uk/pdbsum/6z4s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z4s ProSAT]</span></td></tr> | ||
</table> | </table> | ||
- | == Function == | ||
- | [https://www.uniprot.org/uniprot/NTR1_RAT NTR1_RAT] Receptor for the tridecapeptide neurotensin. It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. | ||
- | <div style="background-color:#fffaf0;"> | ||
- | == Publication Abstract from PubMed == | ||
- | Neurotensin receptor 1 (NTSR1) and related G protein-coupled receptors of the ghrelin family are clinically unexploited, and several mechanistic aspects of their activation and inactivation have remained unclear. Enabled by a new crystallization design, we present five new structures: apo-state NTSR1 as well as complexes with nonpeptide inverse agonists SR48692 and SR142948A, partial agonist RTI-3a, and the novel full agonist SRI-9829, providing structural rationales on how ligands modulate NTSR1. The inverse agonists favor a large extracellular opening of helices VI and VII, undescribed so far for NTSR1, causing a constriction of the intracellular portion. In contrast, the full and partial agonists induce a binding site contraction, and their efficacy correlates with the ability to mimic the binding mode of the endogenous agonist neurotensin. Providing evidence of helical and side-chain rearrangements modulating receptor activation, our structural and functional data expand the mechanistic understanding of NTSR1 and potentially other peptidergic receptors. | ||
- | |||
- | Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism.,Deluigi M, Klipp A, Klenk C, Merklinger L, Eberle SA, Morstein L, Heine P, Mittl PRE, Ernst P, Kamenecka TM, He Y, Vacca S, Egloff P, Honegger A, Pluckthun A Sci Adv. 2021 Jan 27;7(5):eabe5504. doi: 10.1126/sciadv.abe5504. Print 2021 Jan. PMID:33571132<ref>PMID:33571132</ref> | ||
- | |||
- | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
- | </div> | ||
- | <div class="pdbe-citations 6z4s" style="background-color:#fffaf0;"></div> | ||
==See Also== | ==See Also== | ||
*[[Neurotensin receptor|Neurotensin receptor]] | *[[Neurotensin receptor|Neurotensin receptor]] | ||
- | == References == | ||
- | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
- | [[Category: Rattus norvegicus]] | ||
- | [[Category: Synthetic construct]] | ||
[[Category: Deluigi M]] | [[Category: Deluigi M]] | ||
[[Category: Hilge M]] | [[Category: Hilge M]] |
Current revision
Crystal structure of the neurotensin receptor 1 (NTSR1-H4bmx) in complex with the small molecule inverse agonist SR48692
|
Categories: Large Structures | Deluigi M | Hilge M | Klenk C | Klipp A | Merklinger L | Plueckthun A